Salmonella typhi ty2 vi polysaccharide antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Salmonella typhi ty2 vi polysaccharide antigen
Accession Number
DB10803
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated / Other vaccines
Description

Salmonella typhi ty2 vi polysaccharide antigen is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

Synonyms
  • Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Typhim ViSolution25 mcgIntramuscularSanofi Pasteur Limited1995-12-31Not applicableCanada
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Typhim ViInjection, solution25 ug/0.5mLIntramuscularSanofi Pasteur Inc.1994-11-28Not applicableUs
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
VivaximSalmonella typhi ty2 vi polysaccharide antigen (25 mcg) + Hepatitis A Vaccine (160 unit)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada
Categories
UNII
7194H8W3KT
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Acetyl sulfisoxazole.
ActeosideThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Afelimomab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910909
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceCardiovascular Function1
0CompletedTreatmentMajor Depressive Disorder (MDD)1
1Active Not RecruitingTreatmentSalmonella Typhi Infection1
1CompletedPreventionSalmonella Typhi Infection1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction / Reperfusion Injury1
1RecruitingPreventionCardiovascular Disease (CVD)1
2Active Not RecruitingPreventionSalmonella Typhi Infection1
2CompletedPreventionDengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus1
3CompletedPreventionBacterial Infections / Salmonella Infections / Salmonella Typhi Infection1
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4RecruitingDiagnosticSpecific Polysaccharide Antibody Deficiency1
4RecruitingPreventionAging / Inflammatory Reaction1
Not AvailableCompletedBasic ScienceBCG Vaccination1
Not AvailableCompletedBasic ScienceTyphoid Vaccine on Sleep1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular25 ug/0.5mL
SolutionIntramuscular25 mcg
Solution; suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on May 21, 2019 12:26